Upifitamab
Product Specifications
UNSPSC Description
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer[1].
Target Antigen
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/upifitamab.html
Purity
98.77
Solubility
10 mM in DMSO
Smiles
[Upifitamab]
References & Citations
[1]Richardson D, et al. Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076). Gynecologic Oncology, 2022, 166: S48.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99229/Upifitamab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99229/Upifitamab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2254118-43-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
